Changes in oxidative stress markers during azacitidine treatment in patients with myelodysplastic syndromes: a retrospective cohort study

Abstract Oxidative stress has been implicated in myelodysplastic syndromes (MDS), but its longitudinal behavior during azacitidine (AZA) treatment remains poorly characterized. We retrospectively analyzed 22 patients with MDS who received first-line AZA. Peripheral blood WT1 mRNA, serum derivatives of reactive oxygen metabolites (d-ROMs), and reactive oxygen species (ROS) in peripheral blood granulocytes were assessed before treatment and at a selected post-treatment assessment. Among 19 patients evaluable by the Revised International Prognostic Scoring System, WT1 mRNA and d-ROMs levels were higher in the higher-risk group than in the lower-risk group. Log-transformed WT1 mRNA correlated positively with d-ROMs ( r = 0.4515, p = 0.0349), and d-ROMs correlated positively with granulocyte ROS ( r = 0.4819, p = 0.0429); these nominal associations were exploratory. Overall, d-ROMs and granulocyte ROS decreased during AZA treatment. At the selected post-treatment assessment, both markers decreased within the WT1 -decrease group. However, at Cycle 3, neither marker changed significantly in the fixed WT1 -decrease group, whereas RBC transfusion requirements and LDH decreased. Direct between-group comparisons of changes in d-ROMs, granulocyte ROS, RBC transfusion requirements, and LDH were not significant. Because the trajectory groups were defined solely by WT1 change and did not represent established hematologic response categories, these subgroup findings remain exploratory. Changes in oxidative stress markers were not correlated with changes in RBC transfusion requirements or ferritin. These hypothesis-generating findings indicate that oxidative stress markers decrease during AZA treatment, but whether they track WT1 trajectory or hematologic response remains uncertain.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11534390/v1
Primary Topic
Acute Myeloid Leukemia Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Changes in oxidative stress markers during azacitidine treatment in patients with myelodysplastic syndromes: a retrospective cohort study

Hidekazu Hasunuma, Naomi Shimizu, Sanshiro Nakao, Asato Kongoji
1 links
Research Square
Acute Myeloid Leukemia Research
preprint

Changes in oxidative stress markers during azacitidine treatment in patients with myelodysplastic syndromes: a retrospective cohort study

Hidekazu Hasunuma, Naomi Shimizu, Sanshiro Nakao, Asato Kongoji
preprint en

Abstract

Abstract Oxidative stress has been implicated in myelodysplastic syndromes (MDS), but its longitudinal behavior during azacitidine (AZA) treatment remains poorly characterized. We retrospectively analyzed 22 patients with MDS who received first-line AZA. Peripheral blood WT1 mRNA, serum derivatives of reactive oxygen metabolites (d-ROMs), and reactive oxygen species (ROS) in peripheral blood granulocytes were assessed before treatment and at a selected post-treatment assessment. Among 19 patients evaluable by the Revised International Prognostic Scoring System, WT1 mRNA and d-ROMs levels were higher in the higher-risk group than in the lower-risk group. Log-transformed WT1 mRNA correlated positively with d-ROMs ( r = 0.4515, p = 0.0349), and d-ROMs correlated positively with granulocyte ROS ( r = 0.4819, p = 0.0429); these nominal associations were exploratory. Overall, d-ROMs and granulocyte ROS decreased during AZA treatment. At the selected post-treatment assessment, both markers decreased within the WT1 -decrease group. However, at Cycle 3, neither marker changed significantly in the fixed WT1 -decrease group, whereas RBC transfusion requirements and LDH decreased. Direct between-group comparisons of changes in d-ROMs, granulocyte ROS, RBC transfusion requirements, and LDH were not significant. Because the trajectory groups were defined solely by WT1 change and did not represent established hematologic response categories, these subgroup findings remain exploratory. Changes in oxidative stress markers were not correlated with changes in RBC transfusion requirements or ferritin. These hypothesis-generating findings indicate that oxidative stress markers decrease during AZA treatment, but whether they track WT1 trajectory or hematologic response remains uncertain.

Research Square
Toho University (JP), Toho University Medical Center Sakura Hospital (JP)
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon